- Home
- CGEM
as 04-18-2025 1:33pm EST
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 506.1M | IPO Year: | 2021 |
| Target Price: | $32.86 | AVG Volume (30 days): | 520.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.11 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.85 - $30.19 | Next Earning Date: | 05-14-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Cullinan Oncology Inc. (CGEM)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Jones Jeffrey Alan | CGEM | Chief Medical Officer | Feb 25 '25 | Sell | $8.53 | 4,895 | $41,754.35 | 174,164 | |
| SUMER JACQUELYN L | CGEM | Chief Legal Officer | Feb 25 '25 | Sell | $8.53 | 3,756 | $32,038.68 | 136,895 | |
| Michaelson Jennifer | CGEM | Chief Scientific Officer | Feb 25 '25 | Sell | $8.53 | 3,756 | $32,038.68 | 142,004 | |
| AHMED NADIM | CGEM | President and CEO | Feb 25 '25 | Sell | $8.53 | 12,529 | $106,872.37 | 430,621 |
Latest Cullinan Oncology Inc. News
CGEM Breaking Stock News: Dive into CGEM Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid Arthritis
GlobeNewswire
2 months ago
Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
GlobeNewswire
2 months ago
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
Simply Wall St.
3 months ago
Cullinan Therapeutics (NASDAQ:CGEM) Is In A Good Position To Deliver On Growth Plans
GlobeNewswire
3 months ago
Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference
PR Newswire
3 months ago
Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy
GlobeNewswire
5 months ago
Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024
GlobeNewswire
5 months ago
Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Compare CGEM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CGEM Cullinan Oncology Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.